Core Viewpoint - A class action lawsuit has been filed against Petco Health and Wellness Company, Inc. for misleading statements made during the Class Period from January 14, 2021, to June 5, 2025, potentially affecting investors' financial interests [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Petco's pandemic-related growth was unsustainable and that the company's business model, which focuses on premium pet food, was overstated [5]. - Defendants allegedly failed to disclose the true scope of issues affecting Petco's business, including the necessary changes to address these issues and the negative impacts on comparable sales [5]. - The lawsuit asserts that public statements made by the defendants were materially false and misleading, leading to investor damages when the truth was revealed [5]. Group 2: Investor Participation - Investors who purchased Petco securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can submit a form or contact the Rosen Law Firm for more information [3][6]. - A lead plaintiff is needed to represent the class, and interested parties must move the Court by August 29, 2025 [1][3]. Group 3: Rosen Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, further establishing the firm's credibility [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against 3D Systems Corporation due to alleged violations of federal securities laws, encouraging affected investors to come forward before the August 12, 2025 deadline for lead plaintiff applications in a federal securities class action [3][5]. Financial Performance - 3D Systems reported Q4 2024 non-GAAP earnings-per-share of -$0.19, missing consensus estimates by $0.08, with sales revenue of $111 million, reflecting a year-over-year decline of 3.4% and missing estimates by $4.17 million [6]. - For the full year 2024, the company reported sales of $440.1 million, a decrease of 10% compared to the previous year, attributed to lower hardware systems sales due to macroeconomic factors [6]. - In Q1 2025, 3D Systems reported revenue of $94.5 million, down 8% year-over-year, and a net loss of $37 million, or $0.28 per share, more than doubling the loss from Q1 2024 [8]. Stock Price Reaction - Following the Q4 2024 results announcement, 3D Systems' stock price fell by $0.57, or 20.96%, closing at $2.15 per share [7]. - After the Q1 2025 results were released, the stock price dropped by $0.68, or 26.6%, closing at $1.87 per share [9]. Allegations and Legal Context - The complaint against 3D Systems alleges that the company and its executives made false and misleading statements regarding customer spending and the impact on the company's business, as well as the revenue from its Regenerative Medicine Program [5]. - The firm is encouraging anyone with information regarding 3D Systems' conduct to come forward, including whistleblowers and former employees [11].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against 3D Systems Corporation due to alleged violations of federal securities laws, encouraging affected investors to come forward before the August 12, 2025 deadline for lead plaintiff applications in a federal securities class action [2][4]. Financial Performance - 3D Systems reported Q4 2024 non-GAAP earnings-per-share of -$0.19, missing consensus estimates by $0.08, with sales revenue of $111 million, reflecting a 3.4% year-over-year decline [5]. - For the full year 2024, the company reported sales of $440.1 million, a decrease of 10% compared to the previous year, attributed to lower hardware systems sales due to macroeconomic factors [5]. - In Q1 2025, 3D Systems reported revenue of $94.5 million, down 8% year-over-year, and a net loss of $37 million, or $0.28 per share, more than doubling the loss from Q1 2024 [6]. Stock Price Reaction - Following the Q4 2024 results announcement, 3D Systems' stock price fell by $0.57, or 20.96%, closing at $2.15 per share [5]. - After the Q1 2025 results were released, the stock price dropped by $0.68, or 26.6%, to close at $1.87 per share [7]. Allegations and Legal Context - The complaint against 3D Systems alleges that the company and its executives made false or misleading statements regarding the impact of weakened customer spending and the revenue from its Regenerative Medicine Program [4]. - The firm is encouraging anyone with information regarding 3D Systems' conduct to contact them, including whistleblowers and former employees [8].

Core Viewpoint - A class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. for allegedly providing misleading information regarding the safety and clinical trial protocol of its product RP-A501, leading to inflated stock prices and subsequent investor losses [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to securities purchased between February 27, 2025, and May 26, 2025 [1]. - The lawsuit claims that Rocket Pharmaceuticals made positive statements while concealing serious adverse events, including participant deaths, related to RP-A501 [5]. - The company allegedly amended the trial protocol without informing shareholders, which contributed to the misleading nature of the information provided [5]. Group 2: Investor Information - Investors who purchased Rocket Pharmaceuticals securities during the class period may be entitled to compensation without upfront costs through a contingency fee arrangement [2]. - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by August 11, 2025, to represent the class in the lawsuit [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Red Cat Holdings, Inc. due to allegations of misleading statements regarding the company's production capacity and contract values, which have led to significant investor losses [2][4]. Group 1: Company Overview - Red Cat Holdings, Inc. (NASDAQ: RCAT) is involved in the production of small, portable drones for military applications, specifically under the U.S. Army's Short Range Reconnaissance Program [5]. - The company has faced scrutiny for overstating the production capacity of its Salt Lake City facility and the overall value of its contracts, particularly the SRR Contract [4][6]. Group 2: Financial Performance and Stock Impact - Following disclosures about the actual production capacity of the Salt Lake City facility being only 100 drones per month, Red Cat's stock price fell by 8.93% to close at $1.02 per share on July 28, 2023 [8]. - In the first quarter of fiscal year 2025, Red Cat reported losses per share of $0.17, missing consensus estimates by $0.09, and revenue of $2.8 million, missing estimates by $1.07 million [9]. - After a report from Kerrisdale Capital alleged that the SRR Contract was worth only $20 million to $25 million, Red Cat's stock price dropped by 21.54% to close at $8.56 per share on January 17, 2025 [12][13]. Group 3: Legal Proceedings - A federal securities class action has been filed against Red Cat, with a deadline of July 21, 2025, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Red Cat and its executives made materially false and misleading statements regarding the company's business and operations throughout the class period [4][6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against DoubleVerify Holdings, Inc. due to allegations of violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by July 21, 2025 [2][4]. Group 1: Allegations Against DoubleVerify - The complaint alleges that DoubleVerify misled investors by failing to disclose that customers were shifting ad spending from open exchanges to closed platforms, where the company's capabilities were limited [4]. - It is claimed that the monetization of DoubleVerify's high-margin Activation Services was hindered due to the expensive and time-consuming development of technology for closed platforms [4]. - The complaint states that DoubleVerify's competitors were better positioned to incorporate AI into their offerings, negatively impacting the company's competitive edge and profits [4]. - Allegations include that DoubleVerify systematically overbilled customers for ad impressions served to declared bots, and that risk disclosures were materially false and misleading [4]. Group 2: Impact of Allegations - The truth about DoubleVerify's financial struggles was revealed on February 27, 2025, when the company reported lower-than-expected fourth quarter 2024 sales and earnings, leading to a significant stock price drop of $7.83 per share, or 36% [5]. - The stock price fell from a closing price of $21.73 on February 27, 2025, to $13.90 on February 28, 2025, following the disclosure of reduced customer spending and service suspensions [5]. Group 3: Legal Proceedings - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members, overseeing the litigation on behalf of the class [6]. - Any member of the class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [6].

Core Viewpoint - A class action lawsuit has been filed against Fortrea Holdings, Inc. for allegedly making false and misleading statements regarding its financial performance and business prospects during the Class Period from July 3, 2023, to February 28, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Fortrea overestimated revenue contributions from Pre-Spin Projects and overstated cost savings from exiting transition service agreements, leading to inflated EBITDA targets for 2025 [5]. - It is alleged that Fortrea's public statements were materially false and misleading, which resulted in investor damages when the true details became known [5]. Group 2: Participation Information - Investors who purchased Fortrea securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the Rosen Law Firm for more information [3][6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vestis Corporation due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's growth prospects and business performance [3][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $75,000 in Vestis between May 2, 2024, and May 6, 2025, to discuss their legal options [1]. - There is an August 8, 2025, deadline for investors to seek the role of lead plaintiff in a federal securities class action against Vestis [3]. - The complaint alleges that Vestis and its executives concealed material adverse facts regarding the company's ability to grow its business and execute strategic initiatives [5]. Group 2: Financial Performance and Stock Impact - On May 7, 2025, Vestis announced disappointing financial results for Q2 2025, withdrew its revenue guidance for the full fiscal year, and provided lower-than-expected guidance for Q3 2025 [6]. - The company attributed its poor performance to "lost business in excess of new business" and "lower adds over stops," indicating challenges in customer retention and growth [6]. - Following the announcement, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in one day [6].

Core Viewpoint - Rosen Law Firm is reminding purchasers of Ibotta, Inc. securities about a class action lawsuit related to the company's initial public offering and subsequent performance issues, with a lead plaintiff deadline set for June 16, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased Ibotta securities between April 18, 2024, and February 26, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lawsuit alleges that Ibotta made false or misleading statements regarding its business operations and financial health, particularly concerning its contract with Kroger and revenue generation [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Organon To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Organon between October 31, 2024 and April 30, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruq ...